Roche (rhhby) presents encouraging data on sma drug risdiplam – october 4, 2018 – escoliosis de convexidad derecha

Roche ( RHHBY – free report) announced interim encouraging clinical data from two pivotal studies — FIREFISH and SUNFISH — on pipeline candidate, risdiplam at the 23rd international annual congress of the world muscle society in mendoza, argentina.

We note that roche is developing risdiplam, an oral SMN2 splicing modifier, as part of a collaboration with the SMA foundation and PTC therapeutics.

FIREFISH is an open-label, two-part pivotal clinical trial in infants with type 1 SMA. Part 1 was a dose escalation study in 21 infants, while part 2 is a pivotal, single-arm study of risdiplam in approximately 40 infants with type 1 SMA for 24 months, followed by an open-label extension.

The primary objective of part 1 was to assess the safety profile of risdiplam in infants and determine the dose for part 2.

The preliminary data from part 1 of the FIREFISH study showed that infants with type 1 SMA are meeting developmental milestones, including sitting without support.

Six out of 14 infants (43%) were able to sit (with or without support), including three (21%) who achieved unassisted stable sitting after eight months of treatment. Additionally, four infants (29%) demonstrated rolling to the side along with seven (50%) kicking and six (43%) achieving upright head control.

SUNFISH is a two-part, double-blind, placebo-controlled pivotal clinical trial in children and young adults (two to 25 years old) with type 2 and 3 SMA. Part 1 determined the dose for the confirmatory part 2. Roche completed enrollment in part 2 in september 2018.

The preliminary data from part 1 of the SUNFISH study show improvements in motor function in patients with type 2/3 SMA. The follow up studies are ongoing for the confirmatory part 2 portions of both the studies.

Roche is also conducting a third study, JEWELFISH, which is an open-label exploratory trial in people aged 12-60 years with type 2 or 3 SMA, who have been previously treated with SMN-targeting therapy as part of a clinical study.

Notably, biogen’s ( BIIB – free report) spinraza is already approved to treat children and adults with SMA, which reflects the prevailing competition in the market.

Roche has a strong presence in the oncology market. In particular, the company dominates the breast cancer space with strong demand for its HER2 franchise drugs, which include herceptin, perjeta and kadcyla.

The company is making efforts to develop its portfolio beyond oncology into immunology and neuroscience. Roche has more than a dozen investigational medicines in clinical development for diseases like multiple sclerosis, alzheimer`s disease, spinal muscular atrophy, parkinson`s disease, huntington`s disease and autism spectrum disorder.

Year to date, shares of roche have declined 0.1% against the industry’s growth of 11%. Roche’s legacy drugs like herceptin and mabthera are facing competition from biosimilars. Novartis ( NVS – free report) has already launched its biosimilar version of rituxan/ mabthera in europe. Amgen ( AMGN – free report) too has got its biosimilar of avastin.

Did you miss apple’s 9X stock explosion after they launched their iphone in 2007? Now 2018 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025.

Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. Healthcare costs. A bonus zacks special report names this breakthrough and the 5 best stocks to exploit it. Like apple in 2007, these companies are already strong and coiling for potential mega-gains.

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven zacks rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +25.68% per year. These returns cover a period from january 1, 1988 to october 1, 2018. Zacks rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month zacks rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all zacks rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only zacks rank stocks included in zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks ranks stocks can, and often do, change throughout the month. Certain zacks rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.